Abstract
The critical role of mitochondria in cardiomyocyte survival and death has become an exciting field of research in cardiac biology. Indeed, it is accepted that mitochondrial dysfunction plays a crucial role in the pathogenesis of multiple cardiac diseases. Besides the obvious relevance of mitochondria in energy production, calcium homeostasis, and reactive oxygen species (ROS) production, new processes like mitochondrial fusion/fission, phosphorylation and nitrosylation modifications in mitochondrial proteins have been suggested to form part of a cast of key players in cardiac disease. This review describes currently studied drugs and compounds that target mitochondria in the scenario of cardiovascular diseases.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antioxidants / therapeutic use
-
Cardiovascular Agents / chemistry
-
Cardiovascular Agents / therapeutic use*
-
Cardiovascular Diseases / metabolism
-
Cardiovascular Diseases / pathology
-
Cardiovascular Diseases / prevention & control*
-
Cell Death / drug effects
-
Drug Design*
-
Humans
-
Ion Transport / drug effects
-
Membrane Transport Modulators / therapeutic use
-
Mitochondria, Heart / drug effects*
-
Mitochondria, Heart / metabolism
-
Mitochondria, Heart / pathology
-
Mitochondrial Dynamics / drug effects
-
Mitochondrial Proteins / metabolism
-
Mitochondrial Turnover / drug effects
-
Myocytes, Cardiac / drug effects*
-
Myocytes, Cardiac / metabolism
-
Myocytes, Cardiac / pathology
-
Oxidative Stress / drug effects
-
Phosphorylation
-
Protein Processing, Post-Translational / drug effects
-
Reactive Oxygen Species / metabolism
Substances
-
Antioxidants
-
Cardiovascular Agents
-
Membrane Transport Modulators
-
Mitochondrial Proteins
-
Reactive Oxygen Species